Pfizer Wins a Big One in Britain
Pfizer (PFE) investors are breathing easier. On Oct. 12, a British court handed the drugmaker a big victory, rejecting an effort by generic-drug maker Ranbaxy Laboratories to launch a generic version of Lipitor, Pfizer's $12.5 billion blockbuster cholesterol-lowering drug.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.